Marengo Therapeutics

Focus: Marengo Therapeutics is a Cambridge-based monoclonal antibody biotech focused on oncology and gastroenterology. The company is early-stage with a pre-clinical to Phase 1/2 pipeline and no approved products.

Oncology Gastroenterology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Marengo Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Marengo Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

No Drain i.e. Omission of abdominal drain placement

Donor Hepatectomy

N/A

Clinical Trials (1)

NCT06769776Drain vs No Drain After Live Donor Hepatectomy

N/A

Help build intelligence for Marengo Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to contribute to novel mAb development in high-value therapeutic areas (oncology, gastroenterology) at a focused, early-stage biotech
Small company environment enables direct impact on drug discovery and clinical strategy decisions
Cambridge location provides access to top talent networks and pharma ecosystem density

Watch Out For

No active job openings listed; hiring appears limited or inactive at present
Pre-revenue stage with unknown funding and cash runway creates financial stability risk
Minimal public visibility with no publications or recent news makes company trajectory opaque

Generated by Claude from Marengo Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

STAR0602

Advanced Solid Tumors

Phase 1/2

Clinical Trials (1)

NCT05592626A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Phase 1/2

STAR0602

Triple Negative Locally Advanced Non-resectable Breast Cancer

Phase 1/2

Clinical Trials (1)

NCT06827613A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Top TAs: Oncology, Gastroenterology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

2 pipeline

Gastroenterology

1 pipeline

Marketed

Pipeline